This crucial paper (Zhou et al., 2009) highlights the bone-independent effects of NPP1 and, together with our findings, supports the proposition that NPP1 inhibition is a potential therapeutic approach for the treatment of type 2 diabetes. Here, ENPP1 is linked to type 2 diabetes mellitus.